<DOC>
	<DOC>NCT00352963</DOC>
	<brief_summary>This study will evaluate the immunogenicity of the co-administration of different combinations of DTPa, IPV, hepatitis B, Hib and Men C vaccines during the first year of life.</brief_summary>
	<brief_title>Immunogenicity &amp; Safety Study of Combined/Separate Vaccine(s) Against Common Diseases in Infants (2,4,6 Months of Age).</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Poliomyelitis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy male or female infant between, &amp; including, 0 &amp; 7 days of age at the time of the inclusion. Born after a normal gestation period (between 36 &amp; 42 weeks). Written informed consent obtained from the parent/guardian of the subject. Use of any investigational or nonregistered product (drug or vaccine) other than the study vaccine(s) or planned use during the study period. Administration of immunosuppressants or other immunemodifying drugs from birth. Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period. Administration / planned administration of a vaccine not foreseen by the study protocol during the period starting from birth and ending 30 days after the last dose except BCG vaccination if given before the 30day period preceding the administration of the 1st dose of Infanrix penta™ or Infanrix hexa™ in combination with a meningococcal C vaccine. Evidence of previous or intercurrent diphtheria, tetanus, pertussis, polio, hepatitis B, meningococcal C and Hib disease. Evidence of previous diphtheria, tetanus, pertussis, polio, hepatitis B, meningococcal C and Hib vaccination.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>7 Days</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Open, phase 3, Infanrix hexa™, Hib-MenC, co-administered</keyword>
</DOC>